Xinbang Pharmaceutical (002390.SZ) plans to distribute 0.6 yuan for every 10 shares in 2023, excluding interest on May 17
Zhitong Finance App News, Xinbang Pharmaceutical (002390.SZ) announced that in 2023, the company plans to distribute a cash dividend of 0.60 yuan (tax included) to all shareholders for every 10 shares. The share registration date for this equity distribution is May 16, 2024, and the ex-dividend date is May 17, 2024.
Xinbang Pharmaceutical (002390.SZ): Net profit of 58.824,800 yuan in the first quarter increased 11.11% year-on-year
Gelonghui, April 28 | Xinbang Pharmaceutical (002390.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,582 billion yuan, down 1.41% year on year; net profit attributable to shareholders of listed companies was 588.24,800 yuan, up 11.11% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 5881.19 million yuan, up 14.70% year on year; basic earnings per share were 0.03 yuan.
Xinbang Pharmaceutical (002390) Company Brief Review Report: Steady overall operation and rapid release of Chinese medicine tablets
Key investment points The profit side grew rapidly, and cash flow continued to improve. In 2023, the company achieved revenue of 6.461 billion yuan, an increase of 1.75% year on year; net profit to mother was 287 million yuan, up 28.02% year on year; net profit after deduction
Donghai Securities released a research report on April 19 stating that it gave Xinbang Pharmaceuticals (002390.SZ) a purchase rating. The main reasons for the rating include: 1) rapid profit growth and continuous improvement in cash flow; 2) medical servi
Donghai Securities released a research report on April 19 stating that it gave Xinbang Pharmaceuticals (002390.SZ) a purchase rating. The main reasons for the rating include: 1) rapid profit growth and continuous improvement in cash flow; 2) medical services: continuous improvement in operational efficiency and steady progress in discipline construction; 3) pharmaceutical manufacturing: short-term pressure on proprietary Chinese medicines, rapid release of Chinese medicine tablets; 4) pharmaceutical circulation: steady growth in the number of customers and refined control of the supply chain. (Mainichi Keizai Shimbun)
Xinbang Pharmaceutical (002390.SZ): Net profit increased by 28.02% in 2023 to 287 million yuan, plans to distribute 10.0.6 yuan
Gelonghui, April 15 | Xinbang Pharmaceutical (002390.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 6.461 billion yuan, up 1.75% year on year; net profit attributable to shareholders of listed companies was 287 million yuan, up 28.02% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 268 million yuan, up 19.43% year on year; basic income per share was 0.15 yuan; it plans to distribute a cash dividend of 0.60 yuan (tax included) to all shareholders for every 10 shares.
Xinbang Pharmaceutical (002390.SZ) Pediatric Heat-clearing Ning Granules have the therapeutic function of clearing heat and detoxifying
Gelonghui, April 1 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the therapeutic function of the pediatric clean-up and detoxification granules produced by the company is to clear heat and detoxify. It is used for external warmth, internal fever caused by internal heat, high fever, sore throat, heavy cough with phlegm, and dry stools.
Xinbang Pharmaceutical (002390.SZ): The company has subsidiaries that can provide molecular pathology diagnosis services
Gelonghui, April 1 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the company has affiliated institutions that can provide molecular pathology diagnosis services.
Xinbang Pharmaceutical (002390.SZ) has spent 165 million yuan to buy back 1.92% of its shares
Xinbang Pharmaceutical (002390.SZ) issued an announcement. As of March 31, 2024, the company has repurchased a total of shares...
Xinbang Pharmaceutical (002390.SZ): It has developed 9 medicinal and food homologous foods, including Shanggong Tongde Huangjing tablets, Jingshan drink solid drinks, Huier high-solid drinks, and Mengxiang plant solid drinks
Gelonghui, March 27 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that in terms of health products, the company has developed 9 types of medicinal homologous food products, including Shanggong Tongde Huang tablets, Jingshan solid drinks, Huier high-solid drinks, and 5 types of health products such as Shanggong Jiaotai foot bath and traditional Chinese medicine sachets.
Xinbang Pharmaceutical (002390.SZ): Produced Yixin Shu capsules, Maixukang capsules, ginkgo biloba leaves, and dengzhanhuaditin for middle-aged and elderly people
Gelonghui, March 27 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that the company produced Yixinshu capsules, Maxukang capsules, ginkgo biloba leaves, and Dengzhan flower triplin are suitable for middle-aged and elderly people.
Xinbang Pharmaceutical (002390.SZ): In the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue
Gelonghui, March 15 | Xinbang Pharmaceutical (002390.SZ) said on the investor interactive platform that in the first half of 2023, sales expenses accounted for about 5% of revenue, and management expenses accounted for about 6% of revenue. The company effectively controlled various expenses through budget management. The sales expenses incurred in the first half of 2023 were 173.6613 million yuan, a decrease of about 10% over the same period of the previous year; management expenses were 206.643 million yuan, a decrease of about 8% over the same period last year. Currently, the company's various operations are smooth and orderly. The company's business involves the three major sectors of medical services, pharmaceutical distribution and pharmaceutical manufacturing, 20
Xinbang Pharmaceutical (002390.SZ): A total of 1.92% shares have been repurchased
Gelonghui, March 1, 丨 Xinbang Pharmaceutical (002390.SZ) announced that as of February 29, 2024, the cumulative number of shares repurchased by the company was 37,232,540 shares, accounting for 1.92% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the lowest transaction price was 3.31 yuan/share, and the total transaction amount was 165 million yuan (excluding transaction fees).
Express News | Donghai Securities: Focus on innovative pharmaceutical devices, pharmacy chains, blood products and other sectors
Xinbang Pharmaceutical (002390.SZ): The recent wildfires in Guizhou Province had no impact on the company's Chinese herbal medicine planting base
Gelonghui Feb. 26丨An investor asked Xinbang Pharmaceutical (002390.SZ) on the investor interactive platform, “How much impact did the Guizhou wildfires have on the cultivation of Chinese herbal medicines in your company? Does your company have a Chinese herbal medicine planting base in the wildfire area?” The company replied that the recent wildfires in Guizhou Province had no impact on the company's Chinese herbal medicine planting base, and that the company and relevant partners will also actively take corresponding preventive measures.
Express News | Recently, wildfires have occurred in many parts of Guizhou. Local listed companies responded that there was no impact on the cultivation and procurement of Chinese herbal medicines
Express News | There have been frequent wildfires in many parts of Guizhou recently, and many local listed pharmaceutical companies have responded: there is no impact on the supply of medicinal herbs
Xinbang Pharmaceutical (002390.SZ): A total cost of about 148 million yuan to buy back 1.66% of the shares
Gelonghui, Feb. 1 | Xinbang Pharmaceutical (002390.SZ) announced that as of January 31, 2024, the cumulative number of shares repurchased by the company was 32,225,940 shares, accounting for 1.66% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the minimum transaction price was 4.21 yuan/share, and the total transaction amount was about 148 million yuan (excluding transaction fees).
Xinbang Pharma Chairman Buys 14 Million Yuan More Shares
Guizhou Xinbang Pharmaceutical (SHE:002390) Chairman Ji An has increased her personal holdings in the company, citing her confidence in the company's future and development prospects. Anji purchased 3
Xinbang Pharmaceutical (002390.SZ): A total cost of 127 million yuan to buy back 1.42% of the shares
Gelonghui, January 3, 丨 Xinbang Pharmaceutical (002390.SZ) announced that as of December 31, 2023, the cumulative number of shares repurchased by the company was 27,531,540 shares, accounting for 1.42% of the company's total share capital. The highest transaction price was 4.87 yuan/share, the minimum transaction price was 4.42 yuan/share, and the total transaction amount was 127 million yuan (excluding transaction fees).
Xinbang Pharmaceutical (002390.SZ): Chairman An Ji increased its holdings by 3.1062 million shares
Gelonghui, January 2, 丨 Xinbang Pharmaceutical (002390.SZ) announced that on January 2, 2024, the company received a notice from Ms. An Ji, the chairman of the company. Based on her confidence in the company's future sustainable development prospects and recognition of the company's long-term investment value, Ms. Anji increased her shareholding by 3.1062 million shares through the Shenzhen Stock Exchange trading system through centralized bidding transactions on December 29, 2023.
No Data